Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,275
Recruiting: 2,321
Ph III recruiting: 272
Growth YoY: +12.3%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 501–550 of 922 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03987815	Neoadjuvant Nivolumab for Operable Esophageal Carcinoma	unknown	Phase 2	20	Samsung Medical CenterOTHER	1	Dec 17, 2020	clinicaltrials
NCT03254004	Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm	unknown	Phase 2	70	Samsung Medical CenterOTHER	1	Dec 14, 2020	clinicaltrials